J&J MedTech's Next Growth Phase
Johnson & Johnson MedTech CEO Tim Schmid stated that the company is entering its next phase of growth with a focus on surgical robotics, cardiovascular technologies, and portfolio management.
- Surgical robotics
- Cardiovascular technologies
- Targeted portfolio management
J&J MedTech is "leaning in" to high-growth areas of surgery, vision, and cardiovascular health.
The company generated $8.4 billion in revenue last quarter, growing 5.6% year-over-year, driven by strong performance in cardiovascular technologies and gains in wound closure, surgical instrumentation, and vision care.
Author's summary: J&J MedTech focuses on robotics and portfolio realignment.
More News
- Pokemon Legends: Z-A’s Mega Shards Explained (and What to Use Them for)
- Supreme Court Seems Inclined to Limit Race-Based Electoral Districts Under the Voting Rights Act - Chapelboro.com
- Zohran Mamdani: The Fight Begins After Election Day
- Quiz of the Day: It's Menopause Awareness Month - test your knowledge on the facts
- Anderson Cooper Explains How Press Actually Operates Inside the Pentagon: What Hegseth Said 'Is Just a Lie' | Video
- Jackson Cinema is D'Place: Movie Times October 17, 2025 — October 23, 2025
- China lashes out at US "bullying" in worsening spat over Russian oil purchases
- Payroll-delivered emergency savings accounts solution to financial stress
- Who knew that the public would end up supporting striking teachers? Not Danielle Smith and the UCP! - Alberta Politics
- New Music Friday: 15 new releases for a mid-October weekend (17 Oct 2025)